What Mounjaro does to your weight — and what the evidence says

What the SURMOUNT-1 data actually measured

The SURMOUNT-1 trial recruited 2,539 adults living with obesity who did not have type 2 diabetes. Over 72 weeks, participants receiving 15 mg tirzepatide lost an average of around 20–21% of their body weight compared with around 2–3% in the placebo group, as reported in the New England Journal of Medicine's SURMOUNT-1 publication. Lower doses produced meaningful but smaller average reductions: roughly 15% at 5 mg and around 19–20% at 10 mg. It is worth being clear about what those averages mean. Individual responses vary considerably. Some people lost more, some less. The trial ran alongside a reduced-calorie diet and increased physical activity, conditions that mirror the licensed use in practice. If you want a broader overview of how Mounjaro weight loss works in practice, that page sets out the key evidence and expectations clearly. Mounjaro is not licensed for quick weight loss or cosmetic change, the NHS tirzepatide information page puts it plainly: it is for weight management as part of a broader programme. Understanding that framing matters before starting treatment.

Why weight changes under Mounjaro can feel different from dieting alone

Tirzepatide works by activating both GIP and GLP-1 receptors simultaneously, two pathways involved in appetite regulation, gastric emptying and blood-sugar control. The practical result for most people is a significant and sustained reduction in hunger, along with a much lower drive to eat past fullness. Many people also find food feels less central to their day once the medicine is established. That is different from the experience of restriction-based dieting, where hunger typically intensifies over time. None of this means the work of building better habits disappears; in fact, getting enough protein and staying hydrated matters more when appetite is suppressed, because it is easy to undereat key nutrients. The practical guide to losing weight on Mounjaro covers those specifics. It is also worth knowing that some people notice weight gain on Mounjaro, particularly in early weeks, and understanding the reasons behind that can help set more realistic expectations. What the mechanism does explain is why the trial results look so different from older approaches: the medicine changes the hormonal environment around eating, not just the calorie equation on paper.

Who Mounjaro's licence covers and what the prescriber weighs up

Under its UK licence, Mounjaro is approved for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, prediabetes, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI, though, is only the entry point. A prescriber also reviews your medical history, current medicines, and any contraindications before confirming suitability. Certain conditions (including a personal or family history of medullary thyroid carcinoma or pancreatitis) require discussion before treatment can proceed. Pregnancy, breastfeeding and trying to conceive are reasons the medicine is not recommended, and it is not licensed for anyone under 18. For people who are earlier in their research, our page on the weight loss jab Mounjaro explains how it compares with other injectable options and what makes it distinct. The full Mounjaro overview covers the eligibility picture in more detail, and the NICE appraisal (TA1026) sets out the separate NHS criteria if that route is relevant to you.

Cost, prescription access and what a private route looks like

Mounjaro is available through the NHS under phased criteria set out in NICE TA1026, though those criteria are currently strict and access through GP practices is still rolling out. Many people in the UK use a private prescription route instead, either because they do not yet meet NHS thresholds or because they prefer not to wait. For context on what private treatment typically costs, our Mounjaro pricing page covers the current market picture honestly, including what legitimate prices include and why prices that seem far below the market are a reason for caution, given MHRA warnings about counterfeit pens. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber. If approved, treatment is dispatched the same day and arrives with DPD the next working day in plain, unbranded packaging, the pen is exactly what it should be, sourced through the licensed UK supply chain. There are no subscriptions and no auto-renewals; each repeat order goes through the same clinical review as the first. If you have questions before starting, our FAQs page covers many of the practical ones. When you are ready to talk through your situation, speak to our prescribers through a free consultation.